Earnings Releases·Nov 5, 2026, 4:08 PM ET

Guardant Health — Third Quarter 2026 Earnings Summary

Total revenue rose 36% year-over-year to $361.0 million, driven by a 180% surge in screening revenue to $67.6 million and a 25% increase in oncology revenue to $231.3 million.
Full-year 2026 revenue guidance was raised to $1.36–$1.37 billion (38–40% growth), with non-GAAP gross margin guidance increased to 65% and non-GAAP operating expenses raised to $1.105–$1.125 billion.
The company secured FDA approvals for Guardant360 CDx as a companion diagnostic for two AstraZeneca breast cancer therapies and expanded Shield commercial coverage to over 80% of eligible lives.
Non-GAAP net loss narrowed to $38.8 million ($0.29/share) from $48.3 million ($0.39/share) in the prior year, while free cash flow burn improved to $(37.2) million from $(45.8) million.